|
HIC2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62747593179802E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.73594472130389E-12 |
| Normal-vs-Stage2 |
1.041580E-03 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
1.401180E-01 |
| Stage1-vs-Stage3 |
8.777200E-03 |
| Stage1-vs-Stage4 |
4.17300000000731E-05 |
| Stage2-vs-Stage3 |
8.142900E-03 |
| Stage2-vs-Stage4 |
7.182100E-04 |
| Stage3-vs-Stage4 |
1.259000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.63302704692114E-12 |
| Normal-vs-AfricanAmerican |
6.16789952445629E-10 |
| Normal-vs-Asian |
7.24920123928996E-12 |
| Caucasian-vs-AfricanAmerican |
2.940200E-01 |
| Caucasian-vs-Asian |
9.059000E-01 |
| AfricanAmerican-vs-Asian |
1.904180E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.83009981905514E-10 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
2.308200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.36157793110215E-14 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
3.99670296857835E-11 |
| Normal-vs-Age(81-100Yrs) |
5.030600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.760600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.275400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.062000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.429400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.571800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.057000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.70696790036118E-12 |
| Classical-VS-Follicular |
6.621400E-01 |
| Classical-VS-Other |
6.434400E-01 |
| Classical-VS-Normal |
1.66333613549341E-12 |
| Tall-VS-Follicular |
2.30669999989885E-07 |
| Tall-VS-Other |
1.737590E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
7.105000E-01 |
| Follicular-VS-Normal |
1.94420002319617E-09 |
| Other-VS-Normal |
2.484800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.3001600624184E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
4.432100E-04 |
|
|
